Israeli researchers at Technion find two proteins that can suppress Cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Israeli researchers at Technion find two proteins that can suppress Cancer
Now antibodies for cancer treatment are being researched

A team of Israeli researchers at the Technion has discovered two proteins that can suppress cancer and control the cells’ growth and development.

The study was conducted in the laboratory of Prof. Aaron Ciechanover, an Israeli Nobel-prize winner in chemistry, and led by Dr. Yelena Kravtsova-Ivantsiv. The team included research students and physicians from the Rambam, Carmel and Hadassah Medical Centers.

In a paper published in the journal Cell last week, the researchers showed how the proteins could repress cancerous tissues and detailed how a high concentration of a protein called KPC1 and another called p50 in the tissue can protect it from cancerous tumors.

The research also detailed how the ubiquitin process — a cell system responsible for breaking down damaged proteins that can harm cells and tissues and co-discovered by Ciechanover, for which he won the Nobel — has a role in the mechanism.

The study was done on human tumors grown in mice, and samples of human tumors.

Ciechanover told PR Newswire that many more years of research are needed “to establish the research and gain a solid understanding of the mechanisms behind the suppression of the tumors. The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple.”

Ciechanover, now president of the Israel Cancer Society, won the 2004 Nobel Prize in chemistry, for the discovery of ubiquitin-mediated protein degradation. In response to the latest development, Ceichanover warned that it will take many more years before scientists can hope to gain a solid understanding of the mechanisms behind the suppression of cancerous tumors.

“The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple,” he cautioned.

But the current research, which was published in the April 9, 2015 edition of CELL, is also intriguing because it provides further evidence of the relationship between inflammation and cancer, first suggested in 1863 by German pathologist Rudolph Virchow and confirmed over the years.

Ever since the discovery of NF-κB nearly 30 years ago, many scientists have written about its multifaceted involvement in inflammation and cell proliferation, survival and transformation. NF-κB is activated by the ubiquitin system’s KPC1 regulator.

“Overall, KPC1 regulation of NF-κB1 processing appears to constitute an important balancing step among the stimulatory and inhibitory activities of the transcription factor in cell growth control,” the study’s authors conclude.

The Technion team will continue its line of research to find more clues toward solving this puzzle.

Tags : #CancerAntibodies #CancerTreatmentBreakthrough #IsraeliScientists #DrYelenaKravtsova #Technion #CancerTreatment #LatestPharmaNewsAug26

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026